Markus Niggli

Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors

Johnny Mahlangu, Johannes Oldenburg, Ido Paz‐Priel et al. · New England Journal of Medicine · 2018 · 745 citations · Full text

Medicine, Hematology, Pharmacotherapy +14

Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies

Michael U. Callaghan, Claude Négrier, Ido Paz‐Priel et al. · Blood · 2020 · 289 citations · Full text

Medicine, Hematology, Pharmacotherapy +16

Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24‐week, double‐blind, randomized trial

Changyu Pan, Wenying Yang, Jacqueline Barona et al. · Diabetic Medicine · 2008 · 167 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b open-label trial

Steven W. Pipe, Peter W. Collins, Christophe Dhalluin et al. · Blood · 2023 · 78 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

The effect of emicizumab prophylaxis on long‐term, self‐reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies

Mark W. Skinner, Claude Négrier, Ido Paz‐Priel et al. · Haemophilia · 2021 · 56 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +12